<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999686</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS3233-1013</org_study_id>
    <nct_id>NCT01999686</nct_id>
  </id_info>
  <brief_title>PCOS Treatment Using DLBS3233, Metformin, and Combination of Both</brief_title>
  <acronym>POSITIF</acronym>
  <official_title>Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dexa Medica Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6
      months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of
      DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive
      parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be 3 groups of treatment (N = 186), each consist of 62 subjects, as the following:

        -  Treatment I : DLBS3233 100 mg once daily

        -  Treatment II : Metformin XR 750 mg twice daily

        -  Treatment III : DLBS3233 100 mg once daily and Metformin XR 750 mg twice daily.

      Laboratory examination to evaluate metabolic efficacy parameters will be performed at
      baseline, Month 3rd, and end of study (Month 6th).

      Clinical and laboratory examination to evaluate the reproductive efficacy parameters using
      trans-vaginal USG and biomarkers (such as reproductive hormones) will be performed at
      baseline to the end of study.

      Safety examination will be performed at baseline and end of study. Occurrence of adverse
      event will be observed along the study conduct.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA-IR reduction</measure>
    <time_frame>6 months</time_frame>
    <description>HOMA-IR reduction from baseline to Month 6th (end of study)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile improvement</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Lipid profile improvement (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides level) from baseline to Month 3rd and Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of glucose tolerance</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of waist circumference</measure>
    <time_frame>1, 2, 3, 4, 5, and 6 months</time_frame>
    <description>1, 2, 3, 4, 5, and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate: presence of ovulation</measure>
    <time_frame>menstrual cycle of Month 3rd up to that of Month 6th</time_frame>
    <description>Presence of ovulation will be evaluated using trans-vaginal USG to find dominant follicle(s), at the day/period of ovulation, starting from menstrual cycle of Month 3rd up to Month 6th. Measurement of progesterone level will be performed 7 days after the finding of dominant follicle on USG examination to confirm the presence of ovulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of endometrium thickness</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>Change of endometrium thickness will be measured by using trans-vaginal USG at basal condition and at the day/period of ovulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of S/A ratio</measure>
    <time_frame>3 to 6 months</time_frame>
    <description>Improvement from baseline of the S/A ratio (defined as the ratio between stromal and total area of median ovarian section) will be measured using trans-vaginal USG (trans-longitudinal measurement) at Baseline, menstrual cycle of Month 3rd, and menstrual cycle of Month 6th at basal condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Ferriman-Gallwey Score</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Improvement in Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (the end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of free testosterone level</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of free testosterone level from baseline to Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of luteinizing hormone (LH) level</measure>
    <time_frame>6 months</time_frame>
    <description>Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>6 months</time_frame>
    <description>Liver function (levels of serum AST, ALT, alkaline phosphatase) will be measured at baseline and Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>6 months</time_frame>
    <description>Renal function (levels of serum creatinine, BUN) will be measured at baseline and Month 6th (end of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and subjects with events</measure>
    <time_frame>During 6 months</time_frame>
    <description>Adverse events as well as number of events and subjects experiencing the events will be observed and evaluated throughout study period (6 months) and until all adverse events have been recovered or stabilized</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Polycystic Ovary Syndrome (PCOS)</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Treatment I : DLBS3233</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment II : Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment III : Combination DLBS3233 and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS3233</intervention_name>
    <arm_group_label>Treatment I : DLBS3233</arm_group_label>
    <arm_group_label>Treatment III : Combination DLBS3233 and Metformin</arm_group_label>
    <other_name>Inlacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <arm_group_label>Treatment II : Metformin</arm_group_label>
    <arm_group_label>Treatment III : Combination DLBS3233 and Metformin</arm_group_label>
    <other_name>Glumin XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo metformin</intervention_name>
    <description>Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).</description>
    <arm_group_label>Treatment I : DLBS3233</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo DLBS3233</intervention_name>
    <description>Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).</description>
    <arm_group_label>Treatment II : Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent prior to participation in the study.

          2. Female subjects in reproductive age (i.e. 18-40 years) willing to conceive.

          3. Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the
             following (Rotterdam Criteria):

               -  Hyperandrogenism (defined by elevated free testosterone concentration; or
                  Ferriman-Gallwey Score of ≥ 8).

               -  Ovarian dysfunction indicated by menstrual irregularity: oligomenorrhea (cycles
                  of &gt; 35 days), or amenorrhea (no menses in the last of 3 months) after negative
                  screening pregnancy test.

               -  Polycystic ovary as shown by ultrasonography (USG).

          4. Subject with insulin resistance defined by : HOMA-IR of &gt; 2.00.

          5. Subject with body mass index (BMI) of 19-35 inclusive.

          6. Able to take oral medication.

        Exclusion Criteria:

          1. Pregnant or lactating women (urinary pregnancy test will be applied at screening).

          2. Based on previous or current medical (either laboratory or clinical) examination,
             subjects known to have any of the following conditions:

               -  Cushing's syndrome, late onset of congenital adrenal hyperplasia,
                  androgen-secreting tumors, uncontrolled thyroid disease, hyperprolactinemia.

          3. Known to have the following medical condition:

               -  Diabetes mellitus,

               -  Uncontrolled hypertension

               -  Symptomatic cardiovascular diseases:

               -  Acute or chronic infections at baseline.

               -  Any known malignancies.

          4. History of gynecological surgery.

          5. Impaired renal function

          6. Impaired liver function

          7. Medically-assisted weight loss with medications or surgical procedures.

          8. Currently having laparoscopic ovarian diathermy (LOD).

          9. Currently under treatment with in vitro fertilization (IVF) techniques.

         10. Have been regularly taking any of the following medications, within ≤ 3 months prior
             to screening, such as:

               -  Clomiphene citrate

               -  Insulin sensitizers, i.e. metformin and thiazolidinediones

               -  Aromatase inhibitors, such as: anastrozole, letrozole

               -  Glucocorticoids

               -  Gonadotropins

               -  Gonadotropin-releasing hormone agonists (GnRHa)

               -  Oral contraceptive pills (OCPs)

               -  Antiandrogens, such as: spironolactone, cyproterone acetate (CPA), and flutamide

               -  Any traditional or herbal medicines

         11. Participating in other clinical trial within 30 days prior to screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soehartono Ds, Prof. dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Airlangga, Dr. Soetomo Hospital, Surabaya, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arsana Wiyasa IW, Dr. dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya, Dr. Saiful Anwar Hospital, Malang, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Putu Doster Mahayasa, dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Udayana, Sanglah Hospital, Denpasar, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syarief Taufik, dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nusratuddin Abdullah, Dr. dr., SpOG-K, MARS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Hasanuddin, Dr. Wahidin Sudirohusodo Hospital, Makasar, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Iwan Darma Putra, dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lambung Mangkurat, Ulin Banjarmasin Hospital, Banjarmasin, Indonesia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eddy Suparman, Prof. Dr. dr., SpOG-K</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Sam Ratulangi, Prof. Dr. Kandou Hospital, Manado, Indonesia.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Soehartono Ds, Prof. Dr., SpOG-K</last_name>
    <phone>+62811347720</phone>
    <email>batabsby@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Relly Y Primariawan, dr., SpOG-K</last_name>
    <phone>+628123040492</phone>
    <email>relly_yp@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lambung Mangkurat, Ulin Banjarmasin Hospital</name>
      <address>
        <city>Banjarmasin</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwan D Putra, dr., SpOG-K</last_name>
      <phone>+62811503472</phone>
      <email>i_darmaputra@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Iwan D Putra, dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hardyan Sauqi, dr., SpOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Udayana, Sanglah Hospital</name>
      <address>
        <city>Denpasar</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Putu Doster Mahayasa, dr., SpOG-K</last_name>
      <phone>+628123812259</phone>
      <email>dmahayasa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Putu Doster Mahayasa, dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anom Suardika, dr., SpOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Hasanuddin, Dr. Wahidin Sudirohusodo Hospital</name>
      <address>
        <city>Makasar</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nusratuddin Abdullah, Dr., dr., SpOG-K, MARS</last_name>
      <phone>+6281342752561</phone>
      <email>nusraya@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Nusratuddin Abdullah, Dr., dr., SpOG-K, MARS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya, Dr. Saiful Anwar Hospital</name>
      <address>
        <city>Malang</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arsana Wiyasa IW, Dr., dr., SpOG-K</last_name>
      <phone>+62811343876</phone>
      <email>abiyasa9@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Arsana Wiyasa IW, Dr., dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sutrisno Sutrisno, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Widjajanto Ngartjono, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pande M Dwijayasa, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hermawan Wibisono, dr., SpOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Sam Ratulangi, Prof. Dr. Kandou Hospital</name>
      <address>
        <city>Manado</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddy Suparman, Prof., Dr., dr., SpOG-K</last_name>
      <phone>+62811431600</phone>
      <email>obsgyn_manado@yahoo.com.sg</email>
    </contact>
    <investigator>
      <last_name>Eddy Suparman, Prof., Dr., dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Freddy W Wagey, Dr., dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria F Loho, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juneke J Kaeng, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maya E Mewengkang, dr., SpOG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda M Mamengko, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital</name>
      <address>
        <city>Semarang</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syarief Taufik, dr., SpOG-K</last_name>
      <phone>+628112715580</phone>
      <email>tofik_obg@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Syarief Taufik, dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inu Mulyantoro, dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Airlangga, Dr. Soetomo Hospital.</name>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soehartono Ds, Prof., dr., SpOG-K</last_name>
      <phone>+62811347720</phone>
      <email>batabsby@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Soehartono Ds, Prof., dr., SpOG-K</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Budi Santoso, Prof., Dr., dr., SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Relly Y Primariawan, SpOG-K</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovarium syndrome</keyword>
  <keyword>DLBS3233</keyword>
  <keyword>metformin</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>Female</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

